X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the collaboration, Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab for the treatment of first-line advanced cutaneous melanoma.
Lead Product(s): IMC-F106C,Nivolumab
Therapeutic Area: Oncology Product Name: IMC-F106C
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2024
Details:
IMC-M113V is an immunotherapeutic approach designed to specifically eliminate CD4+ cells that are persistently infected with HIV reservoirs. It targets a peptide derived from the Gag protein that is presented by HLA-A*02 on the surface of HIV infected cells.
Lead Product(s): IMC-M113V
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-M113V
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
The emerging IMC-C103C results, where most patients had either no or very low MAGE-A4 expression, are consistent with the RECIST and ctDNA reduction results reported for tebentafusp.
Lead Product(s): IMC-C103C,Atezolizumab
Therapeutic Area: Oncology Product Name: IMC-C103C
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Gadeta is developing ‘201 TCR in its proprietary TEG (T Cells Engineered to Express a Defined Gamma Delta TCR) cell therapy platform as GDT201. Pre-clinical data for GDT201 show promising results across a wide range of colorectal cancer cell lines.
Lead Product(s): GDT201,Tebentafusp-tebn
Therapeutic Area: Oncology Product Name: GDT201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Gadeta
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2022
Details:
KIMMTRAK (tebentafusp) is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Kimmtrak (tebentafusp) is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Medison Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 09, 2022
Details:
The durable responses in heavily pre-treated patients show that our PRAME-targeted bispecific therapy, IMC-F106C, can deliver meaningful benefits to patients across a range of cancer types.
Lead Product(s): IMC-F106C
Therapeutic Area: Oncology Product Name: IMC-F106C
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME.
Lead Product(s): IMC-F106C
Therapeutic Area: Oncology Product Name: IMC-F106C
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Immunocore expects to use the proceeds from the PIPE to fund its oncology and infectious disease clinical pipeline including the continued clinical development of Kimmtrak (tebentafusp) in advanced cutaneous melanoma and ImmTAC clinical candidates targeting MAGE-A4 and PRAME.
Lead Product(s): Tebentafusp,Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Kimmtrak
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 18, 2022
Details:
In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IMC-I109V elicited on-target activity, consistent with mechanism of action and without any adverse events.
Lead Product(s): IMC-I109V
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-I109V
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
